Investigating new therapies for acute myeloid leukemia (AML)
Official title: Acute myeloid leukemia (AML) Research Project
Funded at University of Pennsylvania · NIH-10881943 · Data updated 2026-11-12
This study is looking to find better treatments for people with acute myeloid leukemia (AML) by using special models made from patients' own cancer cells, which will help researchers understand how different genetic changes in AML respond to various therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 5, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $218,826 |
| NIH project number | 5U54CA283759-02 |
| Project ID | NIH-10881943 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia, particularly those with specific genetic mutations.
✕Less likely to help
Patients with other types of leukemia or those who do not have acute myeloid leukemia may not benefit from this research.
What this research studies
This research focuses on improving treatment options for patients with acute myeloid leukemia (AML) by utilizing genetically defined patient-derived xenograft (PDX) models. These models help researchers understand the molecular characteristics of AML and develop targeted therapies aimed at specific genetic alterations. By analyzing thousands of AML samples and their responses to various treatments, the project aims to identify effective therapeutic strategies that could enhance patient outcomes. The research seeks to overcome current limitations in therapy development by creating a comprehensive library of well-characterized AML PDX models.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with AML.
How similar studies have gone: Previous research has shown promise in using genetically defined models to develop targeted therapies for various cancers, indicating a potential for success in this approach.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Carroll, Martin — University of Pennsylvania
- Study coordinator: Carroll, Martin
Related research
Other NIH-funded projects on the same topics.
-
Acute Myeloid Leukemia: Improving Targeted Therapies through Genetically Defined PDX Models
Researchers are using patient-like leukemia models to develop therapies that target specific genetic features of AML to improve survival.
-
A broader genomic risk picture to guide AML treatment
AIM to refine how genetic information guides treatment decisions for adults with acute myeloid leukemia by looking at how inherited and recurrent mutations affect risk.
-
RNA Polymerase II as a Therapeutic Target in AML with RAS Activation
This project explores a new way to treat a common type of blood cancer (AML) by blocking a key machinery (RNA Polymerase II) that cancer cells use when the RAS signaling pathway is overactive.
-
SHP2 and BCL2 inhibitors together for AML growth and resistance
A patient-focused look at whether combining SHP2 inhibitors with a BCL2 inhibitor can slow or stop AML, especially in people whose disease has FLT3 or KIT mutations.
-
Targeting RNA polymerase II in AML with RAS pathway activation
This project tests drugs that block RNA polymerase II to help people whose acute myeloid leukemia has RAS pathway activation and is resistant to FLT3 inhibitors.
-
New treatment approach for myelodysplastic syndrome and acute myeloid leukemia
This project aims to develop a new antibody-based therapy to help people with MDS or AML, especially older or frail patients who cannot tolerate high-dose chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.